Noninvasive Glucose Sensing Uses Mid-Infrared Light
|
By LabMedica International staff writers Posted on 01 Sep 2014 |

Image: The new monitor uses a laser to read blood sugar levels. The laser is directed at the person\'s palm, passes through skin cells and is partially absorbed by sugar molecules, allowing scientists to calculate the level of blood sugar (Photo courtesy of Princeton University, Engineering School).
A laser has been developed to measure people's blood sugar, and the technique could allow diabetics to check their condition without pricking themselves to draw blood.
Bioengineers at the Princeton University (NJ, USA) utilized a hollow-core fiber based optical setup for light delivery and collection along with a broadly tunable quantum cascade laser to obtain spectra from human subjects and use standard chemometric techniques. In vivo glucose sensing using mid-infrared (IR) spectra was conducted with three healthy human subjects starting on an empty stomach with glucose levels were typically around 80 mg/dL at this time to obtain spectra for their low levels.
Light from a pulsed external cavity Quantum Cascade Laser (Daylight Solutions Inc.; San Diego, CA, USA) with a tuning range between 8–10 μm was focused into a 500 μm diameter hollow-core fiber (Opto-Knowledge Systems, Inc.; Torrance, CA, USA) responsible for delivering light onto a region of the human palm between the thumb and index finger. Backscattered light from the skin was collected using a bundle of six fibers, identical in composition and size to the delivery fiber, arranged in a circular fashion around the delivery fiber and coupled directly to a commercial liquid nitrogen cooled mercury cadmium telluride (MCT) detector.
Numerical values for a subject’s blood glucose concentration level were obtained using a commercial electrochemical meter (OneTouch; High Wycombe, UK) prior to the optical study. Up to ten spectra were taken for each concentration, with a single spectral scan taking roughly 20 seconds; upon conclusion of such a set, the subject once again obtained a reading from the commercial meter to ascertain the stability of blood glucose levels throughout the elapsed time period.
The mid-IR spectra obtained in vivo from human skin yield clinically accurate predictions for blood glucose levels for concentrations between 75–160 mg/dL using both partial least-squares regression (PLSR) and derivative spectroscopy techniques with given calibration sets yielded average errors only 2% more than those from a commercial electrochemical meter. The glucose absorption features in mid-IR skin visibly change with respect to increasing concentration, as absorption minima increase in depth and width. The authors concluded that this application of mid-IR light to noninvasive in vivo glucose sensing yields a robust and clinically accurate system that transcends boundaries set in the past which limited the scope of mid-IR in vivo applications.
Claire Gmachl, PhD, a professor of Electrical Engineering and senior author of the study, said, “With this work we hope to improve the lives of many diabetes sufferers who depend on frequent blood glucose monitoring. Because the quantum cascade laser can be designed to emit light across a very wide wavelength range, its usability is not just for glucose detection, but could conceivably be used for other medical sensing and monitoring applications.” The scientists are working on ways make the device much smaller. The study was published on July 1, 2014, in the journal Biomedical Optics Express.
Related Links:
Princeton University
Daylight Solutions
Opto-Knowledge Systems
Bioengineers at the Princeton University (NJ, USA) utilized a hollow-core fiber based optical setup for light delivery and collection along with a broadly tunable quantum cascade laser to obtain spectra from human subjects and use standard chemometric techniques. In vivo glucose sensing using mid-infrared (IR) spectra was conducted with three healthy human subjects starting on an empty stomach with glucose levels were typically around 80 mg/dL at this time to obtain spectra for their low levels.
Light from a pulsed external cavity Quantum Cascade Laser (Daylight Solutions Inc.; San Diego, CA, USA) with a tuning range between 8–10 μm was focused into a 500 μm diameter hollow-core fiber (Opto-Knowledge Systems, Inc.; Torrance, CA, USA) responsible for delivering light onto a region of the human palm between the thumb and index finger. Backscattered light from the skin was collected using a bundle of six fibers, identical in composition and size to the delivery fiber, arranged in a circular fashion around the delivery fiber and coupled directly to a commercial liquid nitrogen cooled mercury cadmium telluride (MCT) detector.
Numerical values for a subject’s blood glucose concentration level were obtained using a commercial electrochemical meter (OneTouch; High Wycombe, UK) prior to the optical study. Up to ten spectra were taken for each concentration, with a single spectral scan taking roughly 20 seconds; upon conclusion of such a set, the subject once again obtained a reading from the commercial meter to ascertain the stability of blood glucose levels throughout the elapsed time period.
The mid-IR spectra obtained in vivo from human skin yield clinically accurate predictions for blood glucose levels for concentrations between 75–160 mg/dL using both partial least-squares regression (PLSR) and derivative spectroscopy techniques with given calibration sets yielded average errors only 2% more than those from a commercial electrochemical meter. The glucose absorption features in mid-IR skin visibly change with respect to increasing concentration, as absorption minima increase in depth and width. The authors concluded that this application of mid-IR light to noninvasive in vivo glucose sensing yields a robust and clinically accurate system that transcends boundaries set in the past which limited the scope of mid-IR in vivo applications.
Claire Gmachl, PhD, a professor of Electrical Engineering and senior author of the study, said, “With this work we hope to improve the lives of many diabetes sufferers who depend on frequent blood glucose monitoring. Because the quantum cascade laser can be designed to emit light across a very wide wavelength range, its usability is not just for glucose detection, but could conceivably be used for other medical sensing and monitoring applications.” The scientists are working on ways make the device much smaller. The study was published on July 1, 2014, in the journal Biomedical Optics Express.
Related Links:
Princeton University
Daylight Solutions
Opto-Knowledge Systems
Latest Clinical Chem. News
- New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
- Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
- Study Compares Analytical Performance of Quantitative Hepatitis B Surface Antigen Assays
- Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
Channels
Molecular Diagnostics
view channel
Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
Primary central nervous system lymphoma (PCNSL) is typically diagnosed through surgical biopsy, which remains the gold standard but carries substantial risk. Operability depends heavily on tumor location,... Read more
New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, marked by poor survival rates and limited treatment options, especially in patients who do not respond to standard therapies.... Read moreHematology
view channel
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channelAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
New Test Measures How Effectively Antibiotics Kill Bacteria
Antibiotics are typically evaluated by how well they inhibit bacterial growth in laboratory tests, but growth inhibition does not always mean the bacteria are actually killed. Some pathogens can survive... Read morePathology
view channel
AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics
Accurately identifying genetic mutations is central to cancer diagnostics and genomic research, but current methods struggle with complex sequencing data and limited clinical samples. Tumor analysis often... Read more
Skin Biopsy Offers New Diagnostic Method for Neurodegenerative Diseases
Transthyretin amyloidosis (ATTR) is a rare, progressive, and highly aggressive disease caused by the misfolding of a specific protein that accumulates as toxic amyloid filaments in multiple organs.... Read moreTechnology
view channelAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







